Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Conditions
Brief summary
This study is conducted in Asia. The aim of this study is to evaluate long term safety and efficacy in patients with diabetes mellitus in routine clinical practice in India.
Interventions
DRUGinsulin degludec/insulin aspart
Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/purchased from the chemist based on physician prescription. No treatment given.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Informed consent obtained before any study-related activities. (Study-related activities are any procedures that are related to recording of data according to the protocol). The historical data including the data before informed consent obtained (e.g., HbA1c (Glycated Haemoglobin ), FPG (Fasting Plasma Glucose), PPPG (Postprandial Plasma Glucose), severe hypoglycaemia before the start of Ryzodeg™ therapy) can be used for baseline data * Patients with insulin requiring diabetes mellitus and who are scheduled to start treatment with Ryzodeg™ based on the clinical judgment of their treating physician
Exclusion criteria
* Known or suspected allergy to Ryzodeg™ any of the active substances or any of the excipients * Previous participation in this study * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * Patients who are or have previously been on Ryzodeg™ therapy * Patients who are participating in other studies or clinical trials * Patients who are pregnant, breast feeding or have the intention of becoming pregnant within the following 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Adverse Events (AEs) | Weeks 0-52 |
Secondary
| Measure | Time frame |
|---|---|
| Serious Adverse Drug Reactions (SADRs) | Weeks 0-52 |
| Adverse Drug Reactions (ADRs) | Weeks 0-52 |
| Severe or Blood glucose (BG) Confirmed hypoglycaemia | Weeks 0-52 |
| Serious Adverse Events (SAEs) | Weeks 0-52 |
| Change in Fasting Plasma Glucose (FPG) | Week 0, week 52 |
| Change in Post Prandial Blood/Plasma Glucose (PPBG/PPPG) | Week 0, week 52 |
| The reason for initiating or intensifying treatment with Ryzodeg™ | Week 0 - week 52 |
| Change in HbA1c (glycosylated haemoglobin) | Week 0, week 52 |
Countries
India
Outcome results
None listed